Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antitrust Concerns Don’t Cloud Merck-Schering Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck and Schering expect limited divestments, including one of their two products in development for colorectal cancer.

You may also be interested in...



Shared Strengths: The Merck And Schering Pipelines

Merck’s acquisition of Schering-Plough brings much-needed late-stage assets, including potential blockbusters like TRA and bocepravir; the combined pipelines also strengthens existing footholds in neuroscience and respiratory drugs.

A Goliath Grows: Pfizer To Buy Wyeth For $68 Billion

Pfizer aims to acquire rival Wyeth in a proposed deal valued at approximately $68 billion, broadening Pfizer's leadership position in the market by creating a drug powerhouse with combined sales of more than $71 billion, based on 2008 revenues

Pink Sheet Podcast: US FDA Power Plays, Vaccine EUA Without The Sponsor, RBG’s Impact On Pharma

Pink Sheet reporter and editors examine the struggle over the FDA’s reputation, whether a coronavirus vaccine could be made available without sponsor cooperation, and the late Supreme Court Justice Ruth Bader Ginsburg’s legacy for pharma.

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel